ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1251

Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Abstract Number: 2174

Current Treatment of Macrophage Activation Syndrome Worldwide: The METAPHOR Project, a PReS/PRINTO Real-life International Survey
Abstract Number: 0632

Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype
Abstract Number: 1388

CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 1798

CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis
Abstract Number: 0585

Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
Abstract Number: 0881

Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica
Abstract Number: 0943

Cytosporone B, a Selective Agonist of Nr4a1, Inhibits Th17 Differentiation and Alleviates Experimental Arthritis in SKG Mice
Abstract Number: 2118

Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis
Abstract Number: 2309

Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren’s Syndrome
Abstract Number: 0286

Damage Associated with Disease-Specific Effects and Diagnostic or Therapeutic Procedures Is Highly Prevalent in IgG4-Related Disease
Abstract Number: 0128

Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study
Abstract Number: L16

Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Abstract Number: 2430

Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
Abstract Number: 1073

Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].